Skip to main content

Dermatologic & Topical Urethral Pharmacotherapy

Topical and intralesional therapies for genital dermatoses (lichen sclerosus, lichen planus, plasma-cell balanitis), urethral-stricture prevention and adjunctive therapy, and regenerative urologic applications. The category includes high-potency topical corticosteroids (the LS workhorse), topical calcineurin inhibitors (steroid-sparing), intralesional corticosteroids and antimitotics for stricture and Peyronie's disease, the Optilume drug-coated balloon (paclitaxel) as a stricture-recurrence-prevention platform, and platelet-rich plasma as the broadest-application regenerative agent.

For oral systemic Peyronie's pharmacotherapy see Sexual Medicine & Andrology — Peyronie's Disease Agents. For lichen sclerosus clinical management see the linked condition page.

  • High-Potency Topical CorticosteroidsClobetasol propionate 0.05% as the LS workhorse — induction, maintenance, and the hard-stop steroid-atrophy / striae safety ceiling. Comparative potency table (clobetasol, halobetasol, betamethasone dipropionate, fluocinonide, mometasone). Pediatric dosing; balanitis-xerotica-obliterans (BXO) protocols.
  • Topical Calcineurin InhibitorsTacrolimus (Protopic) 0.1%/0.03% and pimecrolimus (Elidel) 1% as steroid-sparing options for genital dermatoses. Off-label in LS and lichen planus; FDA boxed warning on theoretical lymphoma risk and the contemporary safety re-evaluation; intermittent maintenance regimens.
  • Intralesional CorticosteroidsTriamcinolone acetonide for urethral stricture (post-DVIU adjunct), bladder-neck contracture, and PD plaque (legacy). Injection-technique pearls; volume / concentration; ACOG 224 hypertrophic-scar parameters; the BNC literature anchored on Trost 2007.
  • Antimitotics & AntifibroticsMitomycin C, 5-fluorouracil, paclitaxel, halofuginone. Intralesional MMC for urethral stricture and BNC; topical 5-FU for PeIN; the rationale for paclitaxel-coated balloon delivery in stricture (the bridge to drug-coated balloon therapy).
  • Drug-Coated Balloon Therapy (Optilume)Optilume drug-coated balloon (paclitaxel) for recurrent anterior urethral stricture. ROBUST I/II/III pivotal trial program; FIRST-CARE protocol; Mahdi anastomotic-stricture data; the contemporary role as a minimally invasive alternative to repeat DVIU and a bridge before urethroplasty.
  • Platelet-Rich Plasma (PRP)Urologic PRP across Peyronie's disease (Ledesma Phase 2, Dachille, Zugail), erectile dysfunction (Asmundo 2024), urethroplasty (graft incorporation), GSM, and stress incontinence. Preparation methods and concentration variability as the central evidence-quality limitation.